Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Dabrafenib + trametinib has both FDA and EMA/EU approval for Non-small cell lung cancer (NSCLC) (BRAF m). Requiring detection by Oncomine Dx Target Test approved as a companion diagnostic for BRAF V600E mutation (2)
Responses rates with combination of dabrafenib/trametinib are approximately 63–64% and interestingly occur in both smokers and non-smokers but toxicities require dose reductions in the real world for the majority of patients (1)
(1) Kelly 2018 Expert Review of Anticancer Therapy 18: 1063-1…